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Abstract Overstimulation of the glutamatergic system
(excitotoxicity) is involved in various acute and chronic
brain diseases. Several studies support the hypothesis that
guanosine-5′-monophosphate (GMP) can modulate gluta-
matergic neurotransmission. The aim of this study was to
evaluate the effects of chronically administered GMP on
brain cortical glutamatergic parameters in mice. Addition-
ally, we investigated the neuroprotective potential of the
GMP treatment submitting cortical brain slices to oxygen
and glucose deprivation (OGD). Moreover, measurements
of the cerebrospinal fluid (CSF) purine levels were
performed after the treatment. Mice received an oral
administration of saline or GMP during 3 weeks. GMP
significantly decreases the cortical brain glutamate binding
and uptake. Accordingly, GMP reduced the immunocontent
of the glutamate receptors subunits, NR2A/B and GluR1
(NMDA and AMPA receptors, respectively) and glutamate
transporters EAAC1 and GLT1. GMP treatment signifi-
cantly reduced the immunocontent of PSD-95 while did not
affect the content of Snap 25, GLAST and GFAP.
Moreover, GMP treatment increased the resistance of
neocortex to OGD insult. The chronic GMP administration
increased the CSF levels of GMP and its metabolites.
Altogether, these findings suggest a potential modulatory
role of GMP on neocortex glutamatergic system by
promoting functional and plastic changes associated to
more resistance of mice neocortex against an in vitro
excitotoxicity event.
Keywords GMP. Guanine-based purines . Glutamatergic
system . Excitotoxicity . Oxygen and glucose deprivation .
Neuroprotection
Abbreviations
GMP Guanosine-5′-monophosphate
OGD Oxygen and glucose deprivation
CSF Cerebrospinal fluid
GFAP Glial fibrillary acid protein
Snap 25 Synaptosomal-associated protein 25
NMDA N-Methyl-D-aspartic
NR2A/B Subunit 2A/B of N-methyl-D-aspartic receptor
AMPA (2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)
propanoic acid)
GluR1 Subunit 1 of AMPA receptor
PSD-95 Postsynaptic density protein 95
EAAC1 Excitatory amino acid carrier 1
GLAST Glutamate/aspartate transporter
M. Ganzella (*) : J. D. Moreira : R. F. Almeida :D. O. Souza
Departamento de Bioquímica, Instituto de Ciências Básicas da
Saúde, Universidade Federal do Rio Grande do Sul,
Rua Ramiro Barcelos, 2600-anexo,
90035-003 Porto Alegre, RS, Brazil
e-mail: ganzellam@hotmail.com
A. E. Böhmer
Instituto de Ciências Biomédicas–Farmacologia,
Universidade de São Paulo,
Sao Paulo, SP, Brazil
J. A. M. Saute
PPG em Ciências Médicas,
Universidade Federal do Rio Grande do Sul,
Porto Alegre, RS, Brazil
S. Holmseth
Centre for Molecular Biology and Neuroscience, Department of
Anatomy, Institute of Basic Medical Sciences, University of Oslo,
0317 Oslo, Norway
Purinergic Signalling (2012) 8:49–58
DOI 10.1007/s11302-011-9258-3
GLT-1 Glutamate transporter-1
GBPs Guanine-based purines
HBSS Hank’s buffered salt solution
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
GTP Guanosine-5′-triphosphate
GDP Guanosine-5′-diphosphate
GUO Guanosine
XAN Xanthine
UA Uric acid
Introduction
Glutamate is the main excitatory neurotransmitter in
mammalian central nervous system. It acts via ionotropic
(ligand-gated ion channel) or metabotropic (coupled to G
proteins) receptors, modulating several essential brain
processes such as learning and memory, pain, ontogeny,
development, and aging [1–4].
However, overstimulation of the glutamatergic system,
which occurs when glutamate levels in the synaptic cleft
increase over the physiological range (excitotoxicity), is
involved in various acute and chronic brain diseases
including neurodegenerative diseases, traumatic brain inju-
ry, cerebral ischemia, and seizures [1, 2, 5, 6]. There are
strong evidences pointing that glutamatergic excitotoxicity
may be prevented by astrocytic glutamate uptake, a process
responsible for maintaining the extracellular glutamate
below toxic levels [7, 8]. In fact, modulators of glutama-
tergic system homeostasis have then been proposed as a
potential therapeutic tool to attenuate excitotoxicity.
Several studies support the hypothesis that guanosine-5′-
monophosphate (GMP) can modulate glutamatergic neuro-
transmission. It has been reported that GMP is able to
inhibit the binding of glutamate and its analogs to brain
membrane preparations [9–16], to prevent cell responses to
glutamate [17–25], and to stimulate glutamate uptake by
astrocytes [26]
The neuroprotective potential of GMP against excitotox-
icity has also been reported both by in vitro as by in vivo
experiments. Hippocampal slices submitted to oxygen and
glucose deprivation (OGD) followed by reperfusion have their
viability restored when GMP is added to the incubation
medium [27–29]. Additionally, GMP prevented seizures and
striatal neuronal damage promoted by quinolinic acid, a
hyper stimulator of the glutamatergic system [30–35].
The aim of this study was to evaluate, for the first time,
the effects of chronic (3 weeks ad libitum) orally
administered GMP on brain cortical glutamatergic param-
eters in mice. We also investigated the neuroprotective
potential of the GMP treatment by submitting brain cortical
slices to OGD. In addition, we aimed to measure the
concentration of purines levels in the cerebrospinal fluid
(CSF) after the administration.
Materials and methods
Reagents
GMP, N-methyl-D-glucamine, bovine serum albumin, pro-
tease and phosphatase inhibitor cocktail and antibodies
against glial fibrillary acid protein (GFAP), Snap 25, and
Actin were from Sigma Chemicals. Antibody against NR2
A/B (N-methyl-D-aspartic receptor subunit) was from
Chemicon; antibodies against subunit 1 of 2-amino-3-(5-
methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid (AMPA) re-
ceptor (GluR1; AMPA receptor subunit) was from UpState;
antibody against postsynaptic density protein 95 (PSD-95)
was from Affinity BioReagents; antibody against excitatory
amino acid carrier 1 (EAAC1) was from Alpha Diagnostic;
antibodies against glutamate/aspartate transporter (GLAST;
batch Ab#314) and glutamate transporter-1 (GLT-1; batch
Ab#360) where from the same preparations as previously
published [36]. The horseradish peroxidase-conjugated
secondary antibody against rabbit and mouse, and the
chemioluminescence (ECL) were from Amersham Pharma-
cia Biotech. X-ray films were from Kodak X-Omat,
Rochester, NY, USA. L-[3H] glutamate (specific activity
30 Ci/mmol) was from Amersham International, UK. The
anesthetic sodium thiopental was from Cristália (Itapira, SP,
Brazil). All other chemicals were of analytical grade or
higher.
Animals
Male adult Swiss albino mice (3–4 months of age, 30–40 g)
were kept on a 12 h light/dark cycle (light on at 7:00 am) at
temperature of 22±1°C, housed in plastic cages (four per
cage) with commercial food ad libitum. All procedures
were carried out according to the Brazilian Society for
Neuroscience and Behavior’s recommendations for animal
care and the US National Institutes of Health guide for the
care and use of laboratory animals, designed to minimize
the suffering and the number of animals used. All
behavioral procedures were conducted between 3:00 and
6:00 PM.
Treatment
The mice received water (control group) or GMP solution
(1.5 mg/ml) for 3 weeks ad libitum from the bottle water.
The GMP dose and time used was based on a previous pilot
study, which indicated that GMP administration for 3 weeks
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with a lower (0.5 mg/mL) or a higher (3 mg/mL) dose, or
only during 1 week, had none or the same effect of the dose
here used, respectively, on glutamate uptake and on in vitro
viability of neocortical slices against OGD (data not
shown). The liquid consumption was monitored every
2 days.
Slice and tissue preparation
The GMP effects were evaluated on brain cortical preparations
based on previous studies indicating that this brain structure is
responsive to guanine-based purines (GBPs) [37, 38].
Briefly after the administration, the animals were
decapitated, their brains were immediately removed and
the cerebral cortices were dissected onto Petri dishes.
Cortices from both brain hemispheres from each animal
were used. The right one was microsliced and the left one
was wholly frozen at −20°C in 25 mM Hepes buffer
(pH 7.4), containing 0.1% sodium dodecyl sulfate (SDS)
and a protease and phosphatase inhibitor cocktail.
The cortical coronal slices (0.4 mm) from the right
parietal area were obtained using a Mcllwain tissue chopper
as previously described [38]. The slices were used for
glutamate uptake or OGD assays.
The intact left cortices were used up to 1 month after
decapitation to isolate plasma membrane or to analyze the
immunocontent of specific proteins.
The animals were randomly assigned to the experiments.
Glutamate uptake
Glutamate uptake was assessed as fully detailed elsewhere
[38]. From each animal, six slices were used. The cortical
slices were separated in two equal sets, placed into
separated 24-well culture plates; one plate was maintained
at 37°C and the other on ice for evaluation of total and Na+-
independent glutamate uptake, respectively, with Hank’s
buffered salt solution (HBSS) containing (in mM):
137 NaCl, 0.63 Na2HPO4, 4.17 NaHCO3, 5.36 KCl,
0.44 KH2PO4, 1.26 CaCl2, 0.41 MgSO4, 0.49 MgCl2, and
5.5 glucose (pH 7.2). For the total glutamate uptake, the
slices were washed once with 1 mL of 37°C HBSS and
then pre-incubated at 37°C for 15 min followed by the
addition of 0.33 Ci/mL L-[3H]glutamate and 100 μM (final
concentration) glutamate. Incubation was stopped after
7 min with two ice-cold washes of 1 mL HBSS,
immediately followed by the addition of 0.5 N NaOH,
which were then kept overnight. Na+-independent uptake
was measured using the same protocol described above,
with differences in the temperature (4°C) and medium
composition (N-methyl-D-glucamine instead of sodium
chloride). Results (Na+-dependent uptake) were considered
as the difference between both uptakes. The incorporated
radioactivity was measured in a Wallac 1409 liquid
scintillation counter.
[3H] Glutamate binding to brain plasma membranes
Brain plasma membrane preparations Plasma membrane
preparations were carried out as previously described [39].
The frozen isolated parietal cortices were thawed at room
temperature and all subsequent isolation procedures were
performed at 4°C. The cortices were homogenized in 0.32 M
sucrose (10% w/v) and centrifuged twice at 1,000×g; both
supernatants were joined and centrifuged at 11,000×g for
20 min. The obtained pellet was osmotically lysed by
resuspension in 5 mM Tris/HCl pH 7.4 for 30 min. This
resuspended pellet was centrifuged at 60,000×g for 120 min
in a sucrose density gradient (49%, 28.5%, and 10%). The
plasma membranes were collected from the interface
between 49% and 28.5% sucrose layers which were then
washed twice in Tris/HCl buffer at 18,000×g for 15 min.
[3H] Glutamate binding protocol The binding assay of [3H]
glutamate was performed at 35°C in small polycarbonate
tubes (total incubation volume 500 μL) containing 10 mM
Tris/HCl pH 7.4 and 40 nM [3H] glutamate [39]. Incubation
was started by the addition of plasma membrane prepara-
tion (50 μg protein). After 30 min, tubes were centrifuged
at 16,000×g for 10 min at 4°C. The supernatant was
discarded and the walls of the tubes and the surface of the
pellets were quickly and carefully rinsed with cold distilled
water. The pellets were solubilized with 0.3 mL of NaOH
0.1 M overnight. Bound radioactivity was measured by
using a Wallac scintillation counter. Unspecific binding
(10–20% of the total binding) was determined by adding
200 μM nonradioactive glutamate to the medium in a
parallel assay. Specific binding was considered as the
difference between total binding and unspecific binding.
Experiments were performed in triplicate.
Western blotting proteins analysis
For Western blotting analysis, the frozen isolated parietal
cortices were thawed at room temperature and then
homogenized in 25 mM Hepes buffer (pH 7.4) containing
0.1% SDS and a protease and phosphatase inhibitors
cocktail and normalized with a sample buffer (4% sodium
dodecylsulfate, 2.1 mM EDTA, 50 mM Tris buffer (pH 7.4),
and 5% β-mercaptoethanol). For each protein evaluated, a
concentration curve (5–50 μg) was previously made in the
same gel in order to determine the amount of protein to be
used in the experiments; accordingly, samples (30 μg
protein/well) with the exception for glutamate transporters
(20 μg protein/well), were subjected to electrophoresis and
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transferred to a nitrocellulose membrane. Membranes were
processed as follows: (1) blocking with 5% bovine serum
albumin for 2 h, (2) incubation with primary antibody
overnight, (3) incubation with horseradish peroxidase conju-
gated secondary antibody for 2 h, (4) chemioluminescence
(ECL) was detected using X-ray films. Protein loading was
controlled by additionally staining blots with β-actin anti-
bodies. The films were scanned and bands intensity was
analyzed using ImageJ (developed at the US National
Institutes of Health and available on the Internet at http://rsb.
info.nih.gov/nih-image/).
Oxygen and glucose deprivation
Six slices were used from each animal. The cortical slices
were separated in two equal sets (control and OGD group),
placed into separated 24-well culture plates, and pre-incubated
for 30 min at 37°C in the modified Krebs–Henseleit solution
containing (in mM): 137 NaCl, 0.63 Na2HPO4, 4.17
NaHCO3, 5.36 KCl, 0.44 KH2PO4, 1.26 CaCl2, 0.41 MgSO4,
0.49 MgCl2, 25 HEPES buffer, and 5.5 glucose (pH 7.2).
After preincubation, the medium in the control plate was
replaced with a new modified Krebs–Henseleit solution and
the plate was maintained at 37°C for 60 min. For ischemic
conditions, the slices were exposed to a model of OGD, as
previously described [40] with some modifications [41].
Briefly, after pre-incubation, OGD slices were washed twice
with the modified Krebs–Henseleit glucose-free solution and
incubated for 60 min (OGD period) at 37°C in a chamber
saturated with nitrogen.
After the 60-min period, the media from both control
and OGD slices were replaced by incubation solution (with
glucose) and cellular viability was immediately verified.
The period of 60 min of ischemic insult was chosen after a
time curve of OGD evaluating cell viability by the 3(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay (data not shown).
Analysis of cellular viability (MTT assay) Cellular viability
assay was performed by colorimetric MTT method. After
the 60-min period, both control and OGD slices were
incubated with 0.5 mg/mL of MTT at 37°C for 20 min. The
formazan product generated during the incubation was
solubilized in dimethyl sulfoxide and measured at 560 and
630 nm. Only viable cells are able to reduce MTT.
CSF purine levels measurement
CSF sampling
For CSF purines concentration measurement, we used
specific mice not used in the others experiments. Mice
were anesthetized with sodium thiopental (60 mg/kg,
10 ml/kg, i.p.) and placed in a stereotaxic apparatus, where
the CSF was drawn (10–20 μl per mouse), with the help of
a magnifying glass, by direct puncture of the cisterna
magna with an insulin syringe (27 gauge×1/2 in length).
All samples were centrifuged at 10,000×g in an Eppendorf
centrifuge for 10 min at 4°C and the supernatant was frozen
at −70°C until analysis.
High-performance liquid chromatography procedure
After being thawed at room temperature, CSF aliquots were
centrifuged at 1,000×g for 5 min for obtaining cell-free
supernatants. High-performance liquid chromatography
(HPLC) was used for determination of purines concentra-
tion [42]. CSF concentrations of the following compounds
were determined: guanosine-5′-triphosphate (GTP),
guanosine-5′-diphosphate (GDP), GMP, guanosine (GUO),
xanthine (XAN), and uric acid (UA). Analyses were
performed with Shimadzu class-VP chromatography system
consisting of a quaternary gradient pump with vacuum
degassing and piston desalting modules, Shimadzu SIL-
10AF auto injector valve with 50 μl loop and a 254-nm UV
detector. Separations were achieved on a Supelco C18 250×
4.6 mm, 5 μm particle size columns. The mobile phase flowed
at a rate of 1.2 mL/min and the column temperature was 24°C.
Buffers composition remained unchanged (A: 150 mmol/
l phosphate buffer, pH 6.0, containing 150 mmol/L KCl; B:
buffer A with 15% acetonitrile). The gradient profile was
modified to the following content of buffer B in the mobile
phase: 0% at 0.00 min, 2% at 0.05 min, 7% at 2.45 min, 50%
at 10.00 min, 100% at 11.00 min, and 0% at 12.40 min.
Samples of 10 μl were injected into the injection valve loop.
Protein determination
Protein concentration was determined by the method of
Lowry [43] for glutamate uptake and by the Coomassie
Blue method [44] for others parameters. Bovine serum
albumin was used as standard.
Statistical analysis
The data obtained are expressed as means±SEM of the
mean. As the variances of the data were homogenous
(analyzed by the Kolmogorov–Smirnov test), we used two-
way analysis of variance (ANOVA) for analyzing the data
from OGD experiment (factors were submission or not to
OGD and treatment) followed by the Bonferroni post test.
Unpaired Student’s t test was used for analyzing the others
results. P<0.05 represents differences statistically signifi-
cant. The number of animals used in each experiment is
described in the figure legends.
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Results
Effects of 3 weeks of oral GMP administration
on functional and structural glutamatergic system
parameters from neocortex
To investigate the GMP effects on glutamatergic system,
we evaluated the glutamate binding to cortical brain plasma
membranes and the glutamate uptake by slices from parietal
cortex. GMP administration by 3 weeks caused a decrease
in [3H] glutamate binding (to 71.57±7.37%; Fig. 1a) and in
[3H] glutamate uptake (to 64.31±5.36%l Fig. 1b) compared
to control animals (P<0.05).
Since both parameters were decreased by GMP adminis-
tration, the immunocontent of some specific proteins related to
the glutamatergic neurotransmission was investigated: sub-
units of glutamatergic receptors (NMDA receptor subunit 2A/
B of N-methyl-D-aspartic receptor (NR2A/B) and AMPA
subunit GluR1), PSD-95 protein (protein implicated in
connecting NMDA receptors to specific signal transduction
pathways), glutamate transporter proteins (GLT-1 and
GLAST—astrocytic, and EAAC1—neuronal), Snap 25
(protein involved in presynaptic vesicular fusion), and GFAP
(astrocytic marker). In parietal cortex samples, oral GMP
administration for 3 weeks reduced the immunocontent of
NR2A/B (to 63±5%), GluR1 (to 69±9%) and PSD-95 (to
73±10%), compared to control animals (Fig. 2a–c, P<0.05).
The immunocontent levels of EAAC1 and GLT-1 were also
reduced to 69±7% and to 86±2%, respectively, compared to
control (Fig. 3a, b, P<0.05). The content of Snap 25
(Fig. 2d), GLAST, and GFAP (Fig. 3c, d) was not affected.
Effects of 3 weeks of oral GMP administration on cell
viability (MTT) of cortical slices submitted to OGD
The two-way ANOVA analysis of variance was performed
using the submission or not to OGDX treatment as factors and
the cell viability (by MTT assay) as the variable. The analysis
showed an interaction between the factors [F(1.30)=11.40, P=
0.0039]. As observed in Fig. 4, the basal viability of cortical
slices was not affected by GMP administration. However,
cellular injury caused by OGD was prevented by GMP orally
administrated for 3 weeks (P<0.05).
Effects of 3 weeks of oral GMP administration on CSF
purines levels
GMP administration increased the CSF levels of GMP (to
120±4%), GUO (to 120±5%), XAN (to 150±8%), and UA
(to 122±4%; Table 1); the GTP levels were not affected.
The CSF GDP content was not reliably detected (data not
shown).
Discussion
Three weeks ad libitum GMP administration (1.5 mg/ml)
attenuated some brain cortical glutamatergic parameters:
glutamate binding and uptake, and the immunocontent of
several proteins related to the glutamate neurotransmission.
In addition, GMP in vivo increased the resistance of
neocortex to OGD (an ex vivo insult). Additionally, it was
also demonstrated that GMP, GUO, XAN, and UA levels
increased in CSF by oral GMP administration.
GMP effects on glutamate binding and on the levels
of proteins related to glutamatergic signaling
Previous works have reported that in vitro GMP is able to
inhibit the binding of glutamate and its analogs to brain
membrane preparations [9–16]. In the present study, chronic
(3 weeks) GMP administration caused a significant de-
crease of neocortex glutamate binding. Two hypotheses
could be raised concerning these results:
Fig. 1 Effects of GMP oral administration for 3 weeks on glutamate
binding to brain cortical plasma membranes (a) and on glutamate
uptake by cortical slices (b). Data are expressed as mean±SEM, n=12
per group for both experiments. Statistical comparison between groups
was performed by unpaired Student’s t test. Asterisk Indicates a
difference from control group at P<0.05; 100% represents 16.3±
1.8 pmol/mg (a) and 0.40±0.02 nmol/mg/min (b)
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1. Chronic GMP administration could increase the levels
of guanine purines in neocortex; this hypothesis is
strengthened by the results of Table 1 indicating that
GMP administration increased GMP CSF levels;
2. The content of neuronal postsynaptic proteins, such as
the ionotropic glutamate receptors subunits, NR2ab and
GluR1 (NMDA and AMPA receptors, respectively) was
decreased by chronic GMP administration. Accordingly,
the level of PSD-95, a protein that is highly enriched
in the post synaptic density, implicated in connecting
NMDA receptors to specific signal transduction path-
ways [45] was also decreased. Additionally, although
there is no evidence in the literature that GMP can
interact with metabotropic glutamate receptors, we
cannot rule out the possibility that GMP may also
affect metabotropic glutamate receptors. This question
remains to be further explored.
Moreover, the levels of Snap 25, a protein essential in
promoting presynaptic vesicular fusion, [46] were not
affected by GMP administration. These results could imply
that GMP effects on glutamate binding mainly affected sites
located at neuronal pos synaptic terminals.
GMP effects on glutamate uptake and glutamate
transporters proteins
Surprisingly when comparing to previous results from our and
other groups, GMP chronic administration decreased the
cortical glutamate uptake. Accordingly, the immunocontent
of the glutamate transporters EAAC1 and GLT-1 (but not
GLAST) were also decreased by GMP administration.
Regarding GBPs, this is the first study to describe their
chronic effects decreasing the glutamate uptake activity, which
was unexpected since it has been shown that in vitro GMP
(apparently through conversion to GUO), is able to enhance
the glutamate uptake by cultured astrocytes and by brain
cortical slices from rats [26, 47, 48]. These data concerning
the reduced glutamate uptake observed in the present work
could be looked at as inconsistent. However, this is the first
study that investigated the effects of a chronic in vivo
administration of GMP on glutamate uptake by cortical slices
of adult mice (which also affected other glutamatergic
parameters), thus pointing that the GMP effects on glutamate
uptake may depend on the experimental models (in vivo or
in vitro), the time and administration route used, and other
parameters simultaneously affected. Accordingly, GMP
Fig. 2 Effects of GMP oral
administration for 3 weeks on
the cortical levels (evaluated by
Western blotting) of glutamate
ionotropic receptors subunits: a
NMDA (NR2a/b); b AMPA
(GluR1), and of glutamatergic
synaptic proteins, c PSD-95; d
Snap 25. Densitometric analysis
of the bands corresponding to
each protein and normalization
to actin allowed comparison
between the groups. Data are
expressed as means±SEM from
three independent experiments,
n=6 per group. Statistical com-
parison between groups was
performed by unpaired Student’s
t test. Asterisk Indicates differ-
ence from control group at P<
0.05. Representative Western
blot images are shown under
each figure. Protein loading of
the gels was controlled by addi-
tionally staining blots with β-
actin antibodies
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chronically administered decreased both glutamate trans-
porters and receptors content. These results raise the question
what the primary effect of GMP: if one is the primary, the
other is more likely a compensatory effect. Knowledge about
the time course of GMP events are still lacking and remain to
be further investigated.
The reduction in glutamate uptake activity appears at
first sight to correlate with the reduction of both EAAC1 and
GLT-1 immunoreactivity. However, EAAC1 contributes
little to the total uptake and most of the glutamate uptake
observed in hippocampal slices is due to GLT-1 [6, 49, 50]
in glutamatergic nerve terminals in spite of the fact that
Fig. 4 Effects of GMP oral administration for 3 weeks on cellular
viability (MTT assay) of cortical slices submitted to ex vivo oxygen
glucose deprivation–OGD. Data are expressed as means±SEM, n=12
animals per group. Statistical comparison among groups was performed
by two-way ANOVA followed by the Bonferroni post test. Asterisk
indicates difference from all others groups at P<0.05
Table 1 Effects of GMP oral administration for 3 weeks on
cerebrospinal fluid (CSF) purines concentration
Treatment Control GMP
CSF purine concentration (μM)
GTP 141±0.05 1.61±0.06
GMP 0.84±0.02 1.01±0.03a
GUO 0.39±0.02 0.47±0.02a
XAN 2.20±0.04 3.30±0.18a
UA 5.25±0.32 6.43±0.22
Data are expressed as means±SEM, n=6 per group. Statistical
comparison between the groups was performed with unpaired
Student’s t test
a Indicates a difference from control group (P<0.05)
Fig. 3 Effects of GMP oral
administration for 3 weeks on
the cortical levels (evaluated by
Western blotting) of glutamate
transporters subunits: a EAAC1,
b GLT-1, c GLAST, and of
astrocytic protein: H–GFAP.
Densitometric analysis of the
bands corresponding to each
protein and normalization to
actin allowed comparison be-
tween the groups. Data are
expressed as means±SEM from
three independent experiments,
n=6 per group. Statistical com-
parison between groups was
performed by unpaired Student’s
t test. Asterisk Indicates differ-
ence from control group at P<
0.05. Representative Western
blot images are shown under
each figure. Protein loading of
the gels was controlled by addi-
tionally staining blots with β-
actin antibodies
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80% of GLT-1 is in astroglia [51]. This raises the question if
the reduced uptake is due to a selective effect on nerve
terminal GLT-1 rather than total GLT-1, which is an
additional aspect to be investigated with more details.
GMP neuroprotective effect against OGD
In the present study, in vivo GMP administration was
neuroprotective against OGD damage through mechanisms
not yet identified, which are under investigation by our
group. However, it could be speculated that the neuro-
protective effect of GMP here observed may be related to
its effects on the glutamatergic system.
Glutamatergic excitotoxicity plays a pivotal role in the
cellular damage during OGD. In brain preparations, OGD
increases the extracellular glutamate concentration from a
low micromolar to a low millimolar range [52, 53] mainly
through the reverse transport activity [54, 55].
Several works have reported that in vitro GMP promotes
neuroprotective effects in hippocampal slices submitted to
OGD [27–29, 37]. These in vitro GMP neuroprotective
effects is suggested to involve a direct interaction with
ionotropic glutamate receptors [28, 29] and/or an increasing
glutamate uptake activity [37]. However, the mechanisms
involved with the neuroprotective effect here observed by in
vivo chronic GMP administration seems to be different from
those promoted by GMP in vitro. It could be speculated that
the in vivo GMP chronic administration, by reducing the
reverse transport activity (decreasing the EAAC1 and GLT-1
transporters level) and the levels of main excitotoxic target
(decreasing the levels of glutamatergic receptors and the
downstream signaling pathway), simultaneously contributed
to a reduction of the extracellular glutamate levels and to a
low responsiveness of neural cells to the excitotoxic stimuli.
GMP effects on CSF purines levels
In a previous study, we reported that acute GMP
administration increases GUO but not GMP CSF level
[34]. In contrast, here GMP chronic administration
increased GMP as well as GUO and their metabolites
CSF levels. These conflicting results are difficult to
interpret as, to our knowledge, there is no work in the
literature addressing GMP CSF transport across the
blood–brain barrier. Of note, the significant production
of GMP metabolites cannot be excluded from playing a
role in the modulatory effects of GMP.
Conclusion
To our knowledge, this is the first study showing the
effects of chronically oral GMP administration on brain
cortical glutamatergic parameters. The results present
here demonstrated the potential modulatory role of GMP
on neocortex glutamatergic system by promoting func-
tional and plastic changes associated to more resistance
of mice neocortex against an in vitro excitotoxicity
event although its mechanism of action remains unclear.
We are continuing to investigate the glutamatergic
modulatory effects of GMP and the mechanisms
underlying these effects.
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